Skip to main content
. 2024 Jul 24;42(30):3561–3569. doi: 10.1200/JCO.23.01995

FIG 3.

FIG 3.

Prediction of ELT benefit by MP on the basis of DFS and BCFI event rate. K-M analysis of (A, B) DFS and (C, D) BCFI comparing ELT versus placebo in patients with MP low-risk (n = 1,160) and patients with MP high-risk (n = 706) tumors. BCFI, breast cancer-free interval; DFS, disease-free survival; ELT, extended letrozole therapy; HR, hazard ratio; K-M, Kaplan-Meier; MP, MammaPrint.